Eli Lilly's Orforglipron Shows Positive Data In Phase 3 ATTAIN-MAINTAIN Trial
I'm PortAI, I can summarize articles.
Eli Lilly announced positive results from its Phase 3 ATTAIN-MAINTAIN trial for orforglipron, a drug for weight maintenance in adults previously treated with Wegovy or Zepbound. The trial showed orforglipron's efficacy in maintaining weight loss, leading to a new drug application submission to the FDA. Detailed results will be presented at a future medical meeting. LLY shares rose 0.32% in pre-market trading.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments